Enhancing Influenza Vaccination in Seniors With TLR (Toll Like Receptor) Agonists

Trial Profile

Enhancing Influenza Vaccination in Seniors With TLR (Toll Like Receptor) Agonists

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Aug 2013

At a glance

  • Drugs Resiquimod (Primary) ; Influenza virus vaccine
  • Indications Influenza virus infections
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Most Recent Events

    • 01 Jun 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 17 Apr 2013 Planned number of patients changed from 120 to 90 as reported by ClinicalTrials.gov record.
    • 01 Apr 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top